Compare · CALT vs NVO
CALT vs NVO
Side-by-side comparison of Calliditas Therapeutics AB (CALT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CALT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 340.7x CALT ($550.4M).
- NVO has hit the wire 11 times in the past 4 weeks while CALT has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 3 for CALT).
- Company
- Calliditas Therapeutics AB
- Novo Nordisk A/S
- Price
- $41.09+4.82%
- $42.01-2.10%
- Market cap
- $550.4M
- $187.53B
- 1M return
- -
- -5.38%
- 1Y return
- -
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 11
- Recent ratings
- 3
- 25
Calliditas Therapeutics AB
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CALT
- SEC Form 15F-12B filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB
- SEC Form 25-NSE filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB
- SEC Form EFFECT filed by Calliditas Therapeutics AB
- Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB
- Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
- SEC Form 25 filed by Calliditas Therapeutics AB
- SEC Form S-8 POS filed by Calliditas Therapeutics AB
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates